Current Report Filing (8-k)
03 10월 2018 - 9:33PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 OR 15(d)
of The Securities Exchange Act of 1934
Date of report (Date of earliest event reported): September 27, 2018
ZOSANO PHARMA CORPORATION
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-36570
|
|
45-4488360
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
34790 Ardentech Court
Fremont, CA 94555
(Address of principal executive offices) (Zip Code)
(510)
745-1200
Registrants telephone number, including area code
Not applicable
(Former
name or former address, if changed since last report.)
Check the appropriate box below
if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (
see
General Instruction A.2. below):
☐
|
Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17
CFR
240.14a-12)
|
☐
|
Pre-commencement
communication pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communication pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule
12b-2
of the Securities Exchange Act of 1934 (17 CFR
§240.12b-2).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Item 1.01
|
Entry into a Material Definitive Agreement.
|
On September 27, 2018, Zosano Pharma Corporation (the Company) entered into a manufacturing and supply agreement (the Agreement)
with Patheon Manufacturing Services LLC (Patheon) for Patheon to provide services related to the manufacture and commercialization of the Companys proprietary product candidate, known as M207 (zolmitriptan microneedle system).
During the term of the Agreement, Patheon will provide manufacturing services to the Company for the manufacturing of M207, including, services related to processing, packaging, labelling and storing M207, in addition to other services such as
stability testing, quality control and assurance and waste disposal.
The Company is required to pay for commercial supply by Patheon in annual base fees
in equal monthly installments in the amounts specified in the Agreement. In addition, the Company is required to pay an additional product fee for units in excess of the number of units covered by the base fee at the price per unit provided for in
the Agreement. The Agreement contains negotiated representations and warranties, indemnification, limitations of liability, and other provisions. The initial term of the Agreement continues until the seventh anniversary of the date on which the
Company receives regulatory approval of M207 in the United States.
The Company may terminate the Agreement if M207 is not granted certain regulatory
approvals or if such regulatory approval is withdrawn under certain circumstances. Either the Company or Patheon may terminate the Agreement for the others uncured material breach, uncured force majeure or bankruptcy or insolvency-related
events.
The foregoing description of the material terms of the Agreement does not purport to be complete and is qualified in its entirety by reference to
the Agreement, which the Company intends to file as an exhibit to its Quarterly Report on Form
8-K
for the quarter ended September 30, 2018. The Company intends to seek confidential treatment for certain
portions of the Agreement pursuant to a Confidential Treatment Request to be submitted to the Securities and Exchange Commission pursuant to Rule
24b-2
under the Securities Exchange Act of 1934, as amended.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
ZOSANO PHARMA CORPORATION
|
|
|
|
|
Dated: October 3, 2018
|
|
|
|
By:
|
|
/s/ John Walker
|
|
|
|
|
|
|
Name: John Walker
|
|
|
|
|
|
|
Title: President and Chief Executive Officer
|
Zosano Pharma (NASDAQ:ZSAN)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Zosano Pharma (NASDAQ:ZSAN)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024
Zosano Pharma Corporation (나스닥)의 실시간 뉴스: 최근 기사 0
More Zosano Pharma Corp News Articles